Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

The company stressed that the regulator has no issues with the safety and efficacy data submitted for the label update ... the clinical profile of Izervay, the only FDA-approved GA treatment ...

Izervay (avacincaptad pegol) is a prescription injection used to treat severe age-related macular degeneration (AMD). Izervay can cause side effects that range from mild to serious. Examples ...

Izervay was approved by the US Food and Drug Administration on August 4 ... Izervay is continuing to be evaluated in an open-label extension study. Astellas is a global life sciences company committed ...

for the supplemental new drug application (sNDA) of Astellas Pharma’s IZERVAY (avacincaptad pegol intravitreal solution), a treatment for geographic atrophy (GA) secondary to age-related macular ...

The FDA has approved a new drug for sight-robbing disease geographic atrophy from Astellas, just a few weeks after the company bought its developer Iveric Bio for $5.9 billion. Izervay ...

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener Astellas Pharma ...

Astellas Pharma Inc. (ALPMY.OB) Astellas Pharma has sought FDA approval to add positive 2-year data to the label of IZERVAY injection for the treatment of Geographic Atrophy, and a decision is ...

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...